ALBERTDAVD · NSE
Albert David Limited
₹848.9
+0.85% (+₹7.15)
Prev. close
₹841.75
Volume
2,601
Delivery %
72.9%
As of
22 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Albert David Limited
Albert David Limited manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs in India and internationally. It offers formulations for parenterals, oral/enterals, topical agents, aerosol, and vision care products. The company exports its products to Latin American, South East Asian and North African countries Albert David Limited was incorporated in 1938 and is headquartered in Kolkata, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Amit Mahla
Headquarters
Kolkata
Employees
1,476
Website
albertdavidindia.comExchange
View on NSE ↗Key stats
Market cap
₹484.48 Cr
P/E ratio (TTM)
21.5
Dividend yield
0.59%
EPS (TTM)
₹39.51
Beta (1Y · daily vs NIFTY 50)
0.64
Beta (5Y · monthly vs NIFTY 50)
1.18
Shares float
20.33 L
EPS · quarter ended Jun 2026
₹56.07
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.5% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹247.45 Cr | ₹313.51 Cr | ₹341.56 Cr | ₹362.46 Cr | ₹345.77 Cr | ₹333.60 Cr | |
| EBITDA | ₹36.33 Cr | ₹56.64 Cr | ₹59.74 Cr | ₹104.43 Cr | ₹32.61 Cr | ₹12.92 Cr |
| ₹22.14 Cr | ₹35.26 Cr | ₹36.17 Cr | ₹75.42 Cr | ₹17.20 Cr | ₹-1.49 Cr | |
| Diluted EPS | ₹38.8 | ₹61.78 | ₹63.39 | ₹132.15 | ₹30.14 | ₹-2.62 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹341.39 Cr | ₹401.23 Cr | ₹423.00 Cr | ₹498.00 Cr | ₹511.00 Cr | ₹519.00 Cr | |
| ₹1.62 Cr | ₹5.66 Cr | ₹5.32 Cr | ₹3.32 Cr | ₹12.32 Cr | ₹29.58 Cr | |
| Stockholders' equity | ₹244.38 Cr | ₹279.47 Cr | ₹312.00 Cr | ₹383.00 Cr | ₹393.00 Cr | ₹392.00 Cr |
Current assets, Non-current assets, Others, Long-term debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹36.61 Cr | ₹40.36 Cr | ₹10.52 Cr | ₹45.50 Cr | ₹-28.44 Cr | ₹-7.66 Cr | |
| Investing cash flow | ₹-36.68 Cr | ₹-39.70 Cr | ₹-5.00 Cr | ₹-33.25 Cr | ₹23.30 Cr | ₹-4.40 Cr |
| ₹-1.71 Cr | ₹-4.88 Cr | ₹-6.36 Cr | ₹-8.27 Cr | ₹11.03 L | ₹11.92 Cr | |
| Capital expenditure | ₹-102.18 Cr | ₹-44.81 Cr | ₹-5.24 Cr | ₹-10.87 Cr | ₹-14.86 Cr | ₹-29.11 Cr |
| End cash position | — | — | ₹1.45 Cr | ₹5.44 Cr | ₹41.73 L | ₹29.91 L |
Debt issued, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22 | Jun 22–Dec 22(3Q) | Mar 23–Dec 23(4Q) | Mar 24–Dec 24(4Q) | Mar 25–Jun 26(6Q) |
|---|---|---|---|---|---|---|---|
| Promoter | 61.35% | 61.64% | 61.96% | 61.99% | 62.04% | 62.13% | 62.24% |
| Public | 38.65% | 38.36% | 38.04% | 38.01% | 37.96% | 37.87% | 37.76% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.49 L Cr | ₹9,410.5 | 84.7 | 14.85 | 15.3% | 0.00 | +12.3% | +51.8% |
| Torrent Pharmaceuticals Limited | ₹1.84 L Cr | ₹4,970 | 77.5 | 21.95 | 25.8% | 1.79 | +21.5% | +36.9% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹691.45 | 179.0 | 13.55 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,161 | 25.8 | 4.27 | 18.6% | 0.46 | +18.4% | +11.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,006.5 | 99.3 | 20.57 | 16.8% | 0.48 | +22.0% | +122.0% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Manipal Health Enterprises Limited | ₹99,047.90 Cr | ₹746.1 | 152.1 | 11.75 | 7.8% | 1.53 | +18.0% | — |
| Dr. Reddy's Laboratories Limited | ₹98,709.15 Cr | ₹1,198.3 | 29.8 | 2.62 | 11.4% | 0.21 | +3.2% | -9.3% |
| Albert David Limited | ₹480.40 Cr | ₹841.75 | 21.3 | 1.23 | -0.4% | 0.08 | -4.0% | +4.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 29
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Albert David Q2 Results FY27: Date and Expectations
Albert David's Q2 FY27 results date is unconfirmed, with the company yet to file a board meeting intimation as of September 9, 2026. Indian regulations require results within 45 days of the quarter end, setting a November 14, 2026, deadline. The upcoming results will be compared to Q2 FY26, which reported a Rs 3 crore loss on Rs 87 crore revenue.
Jammu and Kashmir HC Quashes Drug Case Against Albert David, Orders Probe into Missing Samples
The Jammu and Kashmir High Court quashed criminal proceedings against Albert David Limited in a drug case, ruling the company was denied its right to re-test a sample that never reached the Central Drugs Laboratory. The court also ordered an administrative inquiry into the serious lapses in handling and transmitting the drug sample. This inquiry will examine why the sample went missing and assign responsibility.